You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Guidelines and Advice
Status: In-Review
ID: GL 2-26
Version: 3
Aug 2022
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022
Guidelines and Advice
Jan 2022
Drug
Other Name(s): Femara®
May 2022
Drug
Other Name(s): Tykerb®
Dec 2022
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with anemia due to myelodysplastic syndrome (MDS), according to clinical criteria
May 2022
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
May 2022
Guidelines and Advice
Mar 2022
Guidelines and Advice

Pages